| Similar Articles |
|---|
 |
Salon.com
January 12, 2001
Daniel Forbes |
Ashcroft's nephew got probation after major pot bust Although his arrest for growing 60 plants could have landed him in federal prison, Alex Ashcroft was tried in state court and avoided jail, despite his uncle's crusade for tougher federal drug laws and mandatory prison sentences.   |
Salon.com
January 9, 2001
Arianna Huffington |
The right stuff President-elect Bush should make reform-minded New Mexico Gov. Gary Johnson his drug czar... |
Salon.com
January 5, 2001
Daniel Forbes |
New Mexico thumbs its nose at the war on drugs A panel convened by Gov. Gary Johnson calls for the legalization of marijuana and a shift in focus from penal measures to treatment for drug offenders... |
Salon.com
February 22, 2000
Michael Massing |
The elephant in the room Presidential candidates are silent on the failure of the U.S. war on drugs. |
Salon.com
October 12, 2000
Arthur Allen |
Drug war politics The presidential candidates have not widely touted their plans to deal with drug abuse. Is it because of their own suspect histories? |
Reason
June 2002
Brian Doherty |
John Ashcroft's Power Grab The saga of a troubled -- and troubling -- attorney general... |
Salon.com
January 16, 2001
Alicia Montgomery |
The case for John Ashcroft Clint Bolick of the Institute for Justice says Ashcroft champions civil rights, rules by law and will make a great attorney general... |
Salon.com
January 16, 2001
Bruce Shapiro |
Can John Ashcroft be stopped? If the Clarence Thomas hearings are any guide, disorganized Democrats could be the Republican nominee's best friends... |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. |
Salon.com
February 14, 2001
Earl Ofari Hutchinson |
Another pardon that stinks Clinton pardoned a well-connected cocaine kingpin -- while letting countless low-level, mostly black and Latino, dealers rot in prison... |
Reason
June 2002
Brian Dohery |
Watching the AG Maybe Attorney General John Ashcroft isn't the greatest threat to individual liberty since the Inquisition. But that doesn't mean he hasn't been alarming so far... |
Salon.com
January 8, 2001
Eric Boehlert |
John Ashcroft's big mistake He denied Ronnie White a federal judgeship for being soft on crime, when his real grudge was against his pro-choice politics -- and the move cost him his Senate seat... |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
Salon.com
January 18, 2001
Alicia Montgomery |
Round 2: Ashcroft wins over a Democrat Georgia's Zell Miller says he'll confirm the attorney general designate despite tough grilling on gun control and abortion by Kennedy, Schumer and Feinstein... |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
Salon.com
January 30, 2001
Joe Conason |
The artful dodger John Ashcroft's nose is growing faster than Pinocchio's during his Senate confirmation hearings. As attorney general, will he be as evasive with the truth? |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
June 11, 2010
Brian Orelli |
25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
January 5, 2010
Brian Orelli |
Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
Salon.com
January 16, 2001
Joe Conason |
Ashcroft's tough Sell A segregationist group is banking on the hard-on-crime attorney general nominee to drop a murder conspiracy case against one of its own... |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
Pharmaceutical Executive
April 1, 2011 |
Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access. |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
BusinessWeek
April 28, 2011
Karen Weise |
U.S. Courts Face Backlogs and Layoffs Prominent lawyers warn that court budget cuts will harm the economy. |
The Motley Fool
May 2, 2011
Tim Beyers |
Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment. |
IndustryWeek
February 17, 2010
Jonathan Katz |
Rethinking Drug Testing For years it's been a no-brainer on the plant floor, but what do drug screens really tell us? |
Salon.com
January 11, 2001
Eric Boehlert |
Get Ronnie White, Round 2 In their battle for Attorney General-designate John Ashcroft, Republicans are once again attacking the Missouri Supreme Court justice whose federal judgeship Ashcroft scuttled... |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
Chemistry World
July 2010 |
Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 30, 2011
Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
December 30, 2010
Brian Orelli |
This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly. |
Salon.com
December 22, 2000
Daryl Lindsey |
"A clear and present danger to American women" Pro-choice activists criticize the appointment of conservative John Ashcroft as the Bush administration's attorney general. |
Salon.com
January 17, 2001
Eric Boehlert |
Why won't Rush Limbaugh denounce Ronnie White? Maybe he knows White is no more pro-criminal than his own cousin, Missouri Supreme Court Justice Stephen Limbaugh Jr.... |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
April 15, 2011
Luke Timmerman |
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe? |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
September 20, 2010
Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. |
The Motley Fool
April 28, 2011
Brian Orelli |
Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval. |
